Dexatrim Maker Says Suit Doesn't Show Harm From Carcinogen

Law360, New York (May 23, 2012, 4:16 PM EDT) -- Drugmaker Chattem Inc. asked a California federal judge Monday to toss a proposed class action accusing it of concealing the presence of a carcinogen in its Dexatrim weight loss capsules, saying the customer doesn’t even argue she was harmed by the supplement.

The Sanofi Aventis US LLC subsidiary contends that Joanne Arroyo's complaint relies on hypothetical harm from hexavalent chromium, which a March 2010 report from said was present in Dexatrim Max.

According to the California Office of Environmental Health Hazard Assessment, the ingredient is...
To view the full article, register now.




Case Information

Case Title

Arroyo v. Chattem, Inc.

Case Number



California Northern

Nature of Suit

Other Statutory Actions


Charles R. Breyer

Date Filed

April 27, 2012

Law Firms

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.